Over the weekend, major international talks on biodiversity loss that were set to take place in China were moved because of the coronavirus outbreak.
The first round of negotiations for a Paris-style agreement on biodiversity, which had been due to take place in Kunming, Yunnan province, between 24 and 29 February, has been moved to Rome.
Biodiversity experts and government policy makers had been set to meet in the city in southern China to discuss plans to protect a third of the world’s oceans and land by 2030.
The UN said the decision to move talks was made in consultation with the Chinese government.
Updated
Sixty Italians evacuated from Wuhan arrived at a military base near Rome on Monday.
A passenger who was expected to be onboard the flight remained in Wuhan after contracting a fever, Italian media reported. The group will be quarantined for up to two weeks.
Meanwhile, panic over the virus continues in Italy, with general practitioners and hospital emergency units overwhelmed with people suffering flu symptoms or simply seeking information from professionals. Codacons, the consumers’ group, has called for group tours at popular sites, including the Colosseum in Rome, to be banned. On Friday, Italy announced a state of emergency that will be in place for six months.
Updated
As researchers are racing to develop a vaccine for the Wuhan coronavirus, the British drugmaker GSK has teamed up with the Coalition for Epidemic Preparedness Innovations (CEPI) to aid efforts to produce a vaccine.
GSK, one of the world’s biggest vaccine makers, says it will make its “adjuvant platform technology” available. An adjuvant is added to some vaccines to improve the immune response and means the amount of antigen required per dose can be reduced – allowing more vaccine doses to be produced and made available to more people, which is crucial in a pandemic.
Dr Richard Hatchett, the chief executive of CEPI, says:
Gaining access to GSK’s world-leading adjuvant technology is a huge step forward in developing a vaccine against the novel coronavirus 2019-nCoV. Coupling GSK’s adjuvant systems with the pioneering platform technology we are funding has the potential to make more vaccine available more rapidly – by decreasing the dose of vaccine antigen required to protect each individual.
CEPI, a public-private group based in Norway, is one of several organisations working on a vaccine. It has committed $11m to three programmes led by the companies Inovio Pharmaceuticals and Moderna, and the University of Queensland, with the hope of having a viable vaccine in production within 16 weeks, although testing for safety and efficacy will take much longer.
Meanwhile, a research team at the National Institutes of Health in Maryland has prepared a modified version of a key section of the virus to encourage the body to produce antibodies against the disease. And France’s Pasteur Institute said last Friday that it had set up a taskforce aimed at developing a vaccine against the virus within 20 months.
Updated
In Germany, eight people have tested positive for the virus so far. Seven of them, five Germans and two Chinese nationals, are employees of the car parts supplier Webasto, headquartered in Stockdorf, Bavaria. The eighth is the child of one of the employees.
All eight patients were in a “stable clinical condition” and had only shown “flu-like symptoms”, said a spokesperson for the Bavarian health ministry.
Four of the infected Webasto employees had taken part in a training workshop run by a Chinese employee who only started to feel ill on her return flight to China, where she subsequently tested positive for the 2019-nCov virus.
The company’s headquarters in Stockdorf was disinfected by experts over the weekend and was to remain closed until Tuesday. A further 140 employees were tested for the virus, with 80 of them being ordered to stay indoors and avoid human contact even though their test results had returned negative.
Updated